Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler Announces Clinical Trial Notification for Joint Clinical Trial in Japan

11/12/2021 | 03:29am EST

Eckert & Ziegler announced that the Clinical Trial Notification (CTN) of a joint clinical study with Novartis Pharma K.K. (Japan) was accepted by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for 68Ga-PSMA-11, an investigational radioligand imaging agent and 177Lu-PSMA-617, an investigational radioligand therapy in metastatic prostate cancer. Eckert & Ziegler Radiopharma GmbH is manufacturer of the pharmaceutical 68Ge/68Ga generator GalliaPharm(R), which is used to produce the radiopharmaceutical 68Ga-PSMA-11 for 68Ga PET/CT diagnostics. This diagnostic procedure may be used to detect the presence of prostate-specific membrane antigen (PSMA) on prostate cancer cells, enabling localization of tumors. PSMA is found in high concentration on the surface of prostate cancer cells, making it a potentially effective target for imaging. Investigational imaging agent 68Ga-PSMA-11 has been shown to bind selectively to the PSMA receptor, allowing localization of prostate carcinoma. The same principle may also be used for therapy. In this case, PSMA-617 is attached to the therapeutic radioisotope 177Lu. Prostate cancer is the most common cancer among males in Japan, with over 106,000 cases in 2020, a significantly higher incidence than stomach cancer (95,000 new cases) or lung cancer (94,500 new cases) (IARC Global Cancer Observatory, 2020).


ę S&P Capital IQ 2021
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
01/11ECKERT & ZIEGLER STRAHLEN- UND MEDIZ : Notification and public disclosure of transactions ..
EQ
01/11Eckert & Ziegler Unit Enters Supply Deal for Ytterbium-176 Isotope with US Firm; Shares..
MT
01/10Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
EQ
01/03Eckert & Ziegler Buys Argentinian Nuclear Medicine Firm Tecnonuclear
MT
01/03???????Eckert & Ziegler Acquires Argentinian SPECT Specialist
EQ
01/03Eckert & Ziegler Strahlen- und Medizintechnik AG acquired Tecnonuclear S. A.
CI
2021Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIX..
EQ
2021ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Declaration on the Corporate Governance Code 2021
PU
2021Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil
EQ
2021Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil
CI
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2021 180 M 204 M 204 M
Net income 2021 26,9 M 30,5 M 30,5 M
Net cash 2021 96,9 M 110 M 110 M
P/E ratio 2021 62,9x
Yield 2021 0,53%
Capitalization 1 709 M 1 950 M 1 941 M
EV / Sales 2021 8,98x
EV / Sales 2022 7,03x
Nbr of Employees 841
Free-Float -
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 82,35 €
Average target price 172,00 €
Spread / Average Target 109%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar L÷ffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG-12.49%1 950
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.10%325 363
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
NOVO NORDISK A/S-15.01%223 075